Vaccine trial for hormone-positive breast cancer
Part of Cancer, Skin clinical trials.
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a post-menopausal woman age 18 or older
- Your breast cancer biopsy shows ER-positive and PR-positive (or PR-negative), and HER2-negative
- Your breast cancer is stage I (with tumor size over 1.5 cm if node-negative), stage II, or stage III
- You are well enough to do daily activities (ECOG 0 to 1) and you can sign informed consent
- Your blood counts, liver, and kidney function meet required lab thresholds
- You have not recently had certain cancer treatments or immunotherapy, and you can avoid live vaccines right before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial is testing a new treatment plan for women with high-risk breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It combines radiation therapy after surgery with a CDK4/6 inhibitor, which is a targeted therapy that helps stop cancer cells from dividing. The goal is to see if this combination is safe and well-tolerated, and it may help lower the chance of cancer coming back.
This trial tests a new combination of treatments given before surgery for hormone receptor positive, HER2 negative breast cancer. It uses stereotactic body radiation therapy (SBRT), chemotherapy, and an investigational drug called AK112 to shrink tumors and make surgery easier.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.